NeoGenomics, Inc. (NASDAQ:NEO) Given Consensus Recommendation of “Moderate Buy” by Brokerages

NeoGenomics, Inc. (NASDAQ:NEO) has been given a consensus recommendation of “Moderate Buy” by the ten research firms that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $19.89.

Several brokerages recently weighed in on NEO. Benchmark restated a “buy” rating and issued a $18.00 price target on shares of NeoGenomics in a research note on Tuesday, July 30th. Needham & Company LLC reiterated a “buy” rating and set a $19.00 target price on shares of NeoGenomics in a research report on Tuesday, July 30th. Finally, Stephens restated an “overweight” rating and set a $19.00 price objective on shares of NeoGenomics in a research report on Tuesday, July 30th.

Institutional Trading of NeoGenomics

A number of large investors have recently modified their holdings of the stock. Arizona State Retirement System increased its position in shares of NeoGenomics by 2.0% during the second quarter. Arizona State Retirement System now owns 35,739 shares of the medical research company’s stock worth $496,000 after purchasing an additional 708 shares in the last quarter. Crossmark Global Holdings Inc. boosted its holdings in shares of NeoGenomics by 2.9% in the second quarter. Crossmark Global Holdings Inc. now owns 29,494 shares of the medical research company’s stock valued at $409,000 after acquiring an additional 842 shares in the last quarter. Quadrant Capital Group LLC increased its stake in shares of NeoGenomics by 22.0% during the fourth quarter. Quadrant Capital Group LLC now owns 4,900 shares of the medical research company’s stock worth $79,000 after acquiring an additional 883 shares during the period. Banque Cantonale Vaudoise raised its holdings in NeoGenomics by 6.6% during the first quarter. Banque Cantonale Vaudoise now owns 15,942 shares of the medical research company’s stock worth $251,000 after purchasing an additional 993 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. boosted its holdings in NeoGenomics by 3.3% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 32,505 shares of the medical research company’s stock valued at $451,000 after purchasing an additional 1,030 shares in the last quarter. Hedge funds and other institutional investors own 98.50% of the company’s stock.

NeoGenomics Stock Down 1.2 %

Shares of NEO stock opened at $16.28 on Monday. The stock’s fifty day moving average price is $16.05 and its 200 day moving average price is $14.95. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.01 and a quick ratio of 1.93. NeoGenomics has a 1-year low of $11.03 and a 1-year high of $21.22. The company has a market cap of $2.08 billion, a price-to-earnings ratio of -24.67 and a beta of 1.19.

NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings results on Monday, July 29th. The medical research company reported $0.03 EPS for the quarter. The company had revenue of $164.50 million during the quarter, compared to analysts’ expectations of $161.82 million. NeoGenomics had a negative return on equity of 2.72% and a negative net margin of 12.50%. The firm’s revenue was up 12.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.09) EPS. On average, research analysts expect that NeoGenomics will post -0.22 earnings per share for the current fiscal year.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.